{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:00:25Z","timestamp":1789074025438,"version":"build-2803163510"},"reference-count":78,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Cancer immunotherapy represents a paradigm shift in oncology by leveraging the immune system to target tumors. The therapeutic efficacy of these approaches depends critically on identifying molecular targets that enhance treatment responses while limiting toxicity. CD70, a TNF family member, has emerged as a promising target due to its overexpression in hematologic malignancies and solid tumors contrasted with restricted expression in healthy tissues. This differential expression profile implies that CD70-directed therapies could achieve tumor-specific cytotoxicity with reduced off-target effects. Nevertheless, key challenges persist, including optimizing delivery systems and elucidating the immunological consequences of CD70 modulation. This review synthesizes recent progress in CD70-targeted immunotherapy, evaluating both its therapeutic potential and current constraints to guide future clinical translation.<\/jats:p>","DOI":"10.3389\/fonc.2025.1609840","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:10:39Z","timestamp":1755231039000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["CD70 as a target in cancer immunotherapy: advances, challenges, and future directions"],"prefix":"10.3389","volume":"15","author":[{"given":"Ruchen","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junze","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-018-0006-z","article-title":"Delivery technologies for cancer immunotherapy","volume":"18","author":"Riley","year":"2019","journal-title":"Nat Rev Drug Discov"},{"key":"B2","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13046-021-02215-y","article-title":"The CD70-CD27 axis in oncology: the new kids on the block","volume":"41","author":"Flieswasser","year":"2022","journal-title":"J Exp Clin Cancer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1097\/PPO.0000000000000577","article-title":"Monoclonal antibodies in acute myeloid leukemia-are we there yet","volume":"28","author":"Abaza","year":"2022","journal-title":"Cancer J"},{"key":"B4","doi-asserted-by":"publisher","first-page":"7542","DOI":"10.3390\/ijms23147542","article-title":"New frontiers in monoclonal antibodies for the targeted therapy of acute myeloid leukemia and myelodysplastic syndromes","volume":"23","author":"Gallazzi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-019-0746-1","article-title":"Immune checkpoint blockade and CAR-T cell therapy in hematologic Malignancies","volume":"12","author":"Wang","year":"2019","journal-title":"J Hematol Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.7150\/thno.43991","article-title":"Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors","volume":"10","author":"Yang","year":"2020","journal-title":"Theranostics"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01350","article-title":"CD19 and CD70 dual-target chimeric antigen receptor T-cell therapy for the treatment of relapsed and refractory primary central nervous system diffuse large B-cell lymphoma","volume":"9","author":"Tu","year":"2019","journal-title":"Front Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3880","article-title":"Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer","volume":"6","author":"Jacobs","year":"2015","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.7150\/jca.10360","article-title":"CD70: A potential target in breast cancer","volume":"5","author":"Petrau","year":"2014","journal-title":"J Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"CD70, a novel target of CAR T-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/path.5361","article-title":"CD70 expression correlates with a worse prognosis in Malignant pleural mesothelioma patients via immune evasion and enhanced invasiveness","volume":"250","author":"Inaguma","year":"2020","journal-title":"J Pathol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.10.014","article-title":"CD70 expression patterns in renal cell carcinoma","volume":"43","author":"Jilaveanu","year":"2012","journal-title":"Hum Pathol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S44445","article-title":"Increased CD70 expression is associated with clinical resistance to cisplatin-based chemotherapy and poor survival in advanced ovarian carcinomas","volume":"6","author":"Liu","year":"2013","journal-title":"Onco Targets Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.pharmthera.2015.07.007","article-title":"CD70: An emerging target in cancer immunotherapy","volume":"155","author":"Jacobs","year":"2015","journal-title":"Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.3390\/cancers11101611","article-title":"Screening a broad range of solid and haematological tumour types for CD70 expression using a uniform IHC methodology as potential patient stratification method","volume":"11","author":"Flieswasser","year":"2019","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2016.1158812","article-title":"Therapeutic targeting of CD70 and CD27","volume":"20","author":"Wajant","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20112061","article-title":"Epithelial and dendritic cells in the thymic medulla promote CD4+Foxp3+ regulatory T cell development via the CD27-CD70 pathway","volume":"210","author":"Coquet","year":"2013","journal-title":"J Exp Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.94.12.6346","article-title":"CD27, a member of the tumor necrosis factor receptor family, induces apoptosis and binds to Siva, a proapoptotic protein","volume":"94","author":"Prasad","year":"1997","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1102889","article-title":"CD70-driven costimulation induces survival or Fas-mediated apoptosis of T cells depending on antigenic load","volume":"188","author":"Wensveen","year":"2012","journal-title":"J Immunol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.173.6.3901","article-title":"Signaling through CD70 regulates B cell activation and IgG production","volume":"173","author":"Arens","year":"2004","journal-title":"J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20152008","article-title":"CD70\/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia","volume":"214","author":"Riether","year":"2017","journal-title":"J Exp Med"},{"key":"B22","doi-asserted-by":"publisher","first-page":"298ra119","DOI":"10.1126\/scitranslmed.aab1740","article-title":"Tyrosine kinase inhibitor-induced CD70 expression mediates drug resistance in leukemia stem cells by activating Wnt signaling","volume":"7","author":"Riether","year":"2015","journal-title":"Sci Transl Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22072","article-title":"The costimulatory molecule CD70 is regulated by distinct molecular mechanisms and is associated with overall survival in diffuse large B-cell lymphoma","volume":"52","author":"Bertrand","year":"2013","journal-title":"Genes Chromosomes Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/bjc.2015.412","article-title":"Melanoma-expressed CD70 is involved in invasion and metastasis","volume":"114","author":"Pich","year":"2016","journal-title":"Br J Cancer"},{"key":"B25","doi-asserted-by":"publisher","first-page":"2917","DOI":"10.3390\/cancers12102917","article-title":"Microenvironmental hypoxia induces dynamic changes in lung cancer synthesis and secretion of extracellular vesicles","volume":"12","author":"Tse","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1182\/blood-2016-12-756585","article-title":"CD70 reverse signaling enhances NK cell function and immunosurveillance in CD27-expressing B-cell Malignancies","volume":"130","author":"Al Sayed","year":"2017","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2016.09.042","article-title":"Human regulatory B cells control the T(FH) cell response","volume":"140","author":"Achour","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12201","article-title":"CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell Lymphoma","volume":"41","author":"Deng","year":"2021","journal-title":"Cancer Commun (Lond)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008221","article-title":"CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity","volume":"138","author":"Sauer","year":"2021","journal-title":"Blood"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1093750","article-title":"Preclinical evaluation of CD70-specific CAR T cells targeting acute myeloid leukemia","volume":"14","author":"Wu","year":"2023","journal-title":"Front Immunol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-278218","article-title":"T cells redirected against CD70 for the immunotherapy of CD70-positive Malignancies","volume":"117","author":"Shaffer","year":"2011","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1421","article-title":"Preclinical evaluation of chimeric antigen receptors targeting CD70-expressing cancers","volume":"23","author":"Wang","year":"2017","journal-title":"Clin Cancer Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201545749","article-title":"T cells compete by cleaving cell surface CD27 and blocking access to CD70-bearing APCs","volume":"45","author":"Burchill","year":"2015","journal-title":"Eur J Immunol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.exphem.2006.10.018","article-title":"Metalloprotease inhibitors block release of soluble CD27 and enhance the immune stimulatory activity of chronic lymphocytic leukemia cells","volume":"35","author":"Kato","year":"2007","journal-title":"Exp Hematol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004321","article-title":"Metalloproteinase inhibition reduces AML growth, prevents stem cell loss, and improves chemotherapy effectiveness","volume":"6","author":"Pirillo","year":"2022","journal-title":"Blood Adv"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3816\/CLML.2011.n.041","article-title":"Matrix metalloproteinase-8 is overexpressed in Waldenstrom\u2019s macroglobulinemia cells, and specific inhibition of this metalloproteinase blocks release of soluble CD27","volume":"11","author":"Zhou","year":"2011","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B37","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-023-03422-6","article-title":"Preclinical development and evaluation of nanobody-based CD70-specific CAR T cells for the treatment of acute myeloid leukemia","volume":"72","author":"Cheng","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.152.4.1762","article-title":"Characterization of the human CD27 ligand, a novel member of the TNF gene family","volume":"152","author":"Hintzen","year":"1994","journal-title":"J Immunol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1097\/01.ju.0000158121.49085.ba","article-title":"CD70: a new tumor specific biomarker for renal cell carcinoma","volume":"173","author":"Junker","year":"2005","journal-title":"J Urol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2883","article-title":"Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates","volume":"66","author":"Law","year":"2006","journal-title":"Cancer Res"},{"key":"B42","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.bjc.6603222","article-title":"CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding","volume":"95","author":"Adam","year":"2006","journal-title":"Br J Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012909","article-title":"CD70 identifies alloreactive T cells and represents a potential target for prevention and treatment of acute GVHD","volume":"8","author":"Verma","year":"2024","journal-title":"Blood Adv"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.30830","article-title":"Tumor associated CD70 expression is involved in promoting tumor migration and macrophage infiltration in GBM","volume":"141","author":"Ge","year":"2017","journal-title":"Int J Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2023.03.003","article-title":"Rabies virus glycoprotein 29 (RVG29) promotes CAR-T immunotherapy for glioma","volume":"259","author":"Ji","year":"2023","journal-title":"Transl Res"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03172-x","article-title":"Enhancement of CD70-specific CAR T treatment by IFN-gamma released from oHSV-1-infected glioblastoma","volume":"71","author":"Zhu","year":"2022","journal-title":"Cancer Immunol Immunother"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-024-01525-w","article-title":"IL-15-secreting CAR natural killer cells directed toward the pan-cancer target CD70 eliminate both cancer cells and cancer-associated fibroblasts","volume":"17","author":"Van den Eynde","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012202","article-title":"CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell Malignancy","volume":"8","author":"Guo","year":"2024","journal-title":"Blood Adv"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2024.101889","article-title":"CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep Med"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022017414","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01397-y","article-title":"Payload diversification: a key step in the development of antibody-drug conjugates","volume":"16","author":"Conilh","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.124.268509","article-title":"CD70-targeted immuno-PET\/CT imaging of clear cell renal cell carcinoma: A translational study","volume":"65","author":"Zhou","year":"2024","journal-title":"J Nucl Med"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06672-3","article-title":"ImmunoPET\/CT imaging of clear cell renal cell carcinoma with [(18)F]RCCB6: a first-in-human study","volume":"51","author":"Wu","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.06.020","article-title":"(18)F]RCCB6 immuno-positron emission tomography\/computed tomography for postoperative surveillance in clear cell renal cell carcinoma: A pilot clinical study","volume":"86","author":"Wu","year":"2024","journal-title":"Eur Urol"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00189-2","article-title":"Navigating CAR-T cells through the solid-tumour microenvironment","volume":"20","author":"Hou","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2018.03.002","article-title":"Driving CARs on the uneven road of antigen heterogeneity in solid tumors","volume":"51","author":"Chen","year":"2018","journal-title":"Curr Opin Immunol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"e970027","DOI":"10.4161\/21624011.2014.970027","article-title":"Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment","volume":"3","author":"Beatty","year":"2014","journal-title":"Oncoimmunology"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2013644117","article-title":"CXCR4 inhibition in human pancreatic and colorectal cancers induces an integrated immune response","volume":"117","author":"Biasci","year":"2020","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2119463119","article-title":"Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack","volume":"119","author":"Wang","year":"2022","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.954992","article-title":"Managing the TME to improve the efficacy of cancer therapy","volume":"13","author":"Bilotta","year":"2022","journal-title":"Front Immunol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.7.4919","article-title":"Administration of a CD25-directed immunotoxin, LMB-2, to patients with metastatic melanoma induces a selective partial reduction in regulatory T cells","volume":"179","author":"Powell","year":"2007","journal-title":"vivo J Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"134ra62","DOI":"10.1126\/scitranslmed.3003330","article-title":"CD25 blockade depletes and selectively reprograms regulatory T cells in concert with immunotherapy in cancer patients","volume":"4","author":"Rech","year":"2012","journal-title":"Sci Transl Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820388116","article-title":"Depletion of regulatory T cells in tumors with an anti-CD25 immunotoxin induces CD8 T cell-mediated systemic antitumor immunity","volume":"116","author":"Onda","year":"2019","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-0386","article-title":"Stimulation of natural killer cell-mediated tumor immunity by an IL15\/TGFbeta-neutralizing fusion protein","volume":"76","author":"Ng","year":"2016","journal-title":"Cancer Res"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000493","article-title":"Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1\/IL-15 superagonist","volume":"8","author":"Knudson","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2022.2083755","article-title":"PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors","volume":"11","author":"Staniszewska","year":"2022","journal-title":"Oncoimmunology"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-2931","article-title":"Preclinical development and evaluation of allogeneic CAR T cells targeting CD70 for the treatment of renal cell carcinoma","volume":"82","author":"Panowski","year":"2022","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abe7378","article-title":"SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma","volume":"13","author":"Choe","year":"2021","journal-title":"Sci Transl Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2013.1578","article-title":"Radiation-induced modulation of costimulatory and coinhibitory T-cell signaling molecules on human prostate carcinoma cells promotes productive antitumor immune interactions","volume":"29","author":"Bernstein","year":"2014","journal-title":"Cancer Biother Radiopharm"},{"key":"B71","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell Malignancies: Is success a low-hanging fruit","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-23-0677","article-title":"Knocking out CD70 rescues CD70-specific nanoCAR T cells from antigen-induced exhaustion","volume":"12","author":"De Munter","year":"2024","journal-title":"Cancer Immunol Res"},{"key":"B73","doi-asserted-by":"publisher","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES(R): A review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B74","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1158\/1541-7786.MCR-19-0582","article-title":"Antibody-drug conjugates: A comprehensive review","volume":"18","author":"Khongorzul","year":"2020","journal-title":"Mol Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102975","article-title":"CAR-NK cells: A promising cellular immunotherapy for cancer","volume":"59","author":"Xie","year":"2020","journal-title":"EBioMedicine"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107709","article-title":"Molecular basis and therapeutic implications of CD40\/CD40L immune checkpoint","volume":"219","author":"Tang","year":"2021","journal-title":"Pharmacol Ther"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2023.2167189","article-title":"The emerging landscape of novel 4-1BB (CD137) agonistic drugs for cancer immunotherapy","volume":"15","author":"Claus","year":"2023","journal-title":"MAbs"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1609840\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T04:10:40Z","timestamp":1755231040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1609840\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":78,"alternative-id":["10.3389\/fonc.2025.1609840"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1609840","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"article-number":"1609840"}}